title: Sensitivity in detecting osseous lesions depends on anatomic localization: planar bone scintigraphy versus 18F PET.
abstract: Radionuclide bone scanning (RNB) is considered to be the most practical screening technique for assessing the entire skeleton for skeletal metastases. However, RNB has been shown to be of lower sensitivity than MRI and CT in detecting osteolytic metastases. A prospective study was designed to evaluate the accuracy of planar RNB versus tomographic bone imaging with 18F-labeled NaF and PET (18F PET) in detecting osteolytic and osteoblastic metastases and its dependency on their anatomic localization.
  
  
  METHODS
  Forty-four patients with known prostate, lung or thyroid carcinoma were examined with both planar RNB and 18F PET. A panel of reference methods including MRI of the spine, 1311 scintigraphy, conventional radiography and spiral CT was used as the gold standard. RNB and 18F PET were compared by a lesion-by-lesion analysis using a five-point score for receiver operating characteristic (ROC) curve analysis.
  
  
  RESULTS
  18F PET showed 96 metastases (67 of prostate carcinoma and 29 of lung or thyroid cancer), whereas RNB revealed 46 metastases (33 of prostate carcinoma and 13 of lung or thyroid cancer). All lesions found with RNB were also detected with 18F PET. Compared with 18F PET and the reference methods, RNB had a sensitivity of 82.8% in detecting malignant and benign osseous lesions in the skull, thorax and extremities and a sensitivity of 40% in the spine and pelvis. The area under the ROC curve was 0.99 for 18F PET and 0.64 for RNB.
  
  
  CONCLUSIONS
  18F PET is more sensitive than RNB in detecting osseous lesions. With RNB, sensitivity in detecting osseous metastases is highly dependent on anatomic localization of these lesions, whereas detection rates of osteoblastic and osteolytic metastases are similar. Higher detection rates and more accurate differentiation between benign and malignant lesions with 18F PET suggest the use of 18F PET when possible.
authors.affiliation: Department of Nuclear Medicine, University Hospital, Ulm, Germany.
authors.forename: H
authors.initials: H
authors.lastname: Schirrmeister
authors.forename: A
authors.initials: A
authors.lastname: Guhlmann
authors.forename: K
authors.initials: K
authors.lastname: Elsner
authors.forename: J
authors.initials: J
authors.lastname: Kotzerke
authors.forename: G
authors.initials: G
authors.lastname: Glatting
authors.forename: M
authors.initials: M
authors.lastname: Rentschler
authors.forename: B
authors.initials: B
authors.lastname: Neumaier
authors.forename: H
authors.initials: H
authors.lastname: Träger
authors.forename: K
authors.initials: K
authors.lastname: Nüssle
authors.forename: S N
authors.initials: SN
authors.lastname: Reske
mesh_terms: D001859:Bone Neoplasms / Q000000981:diagnostic imaging* / Q000556:secondary*; D005188:False Negative Reactions; D005462:Fluorine Radioisotopes; D006801:Humans; D008175:Lung Neoplasms / Q000000981:diagnostic imaging; D008279:Magnetic Resonance Imaging; D008297:Male; D011446:Prospective Studies; D011471:Prostatic Neoplasms / Q000000981:diagnostic imaging*; D019275:Radiopharmaceuticals; D012969:Sodium Fluoride; D013669:Technetium Tc 99m Medronate; D013964:Thyroid Neoplasms / Q000000981:diagnostic imaging; D014055:Tomography, Emission-Computed; D015899:Tomography, Emission-Computed, Single-Photon; D014057:Tomography, X-Ray Computed
chemical_list: D005462:Fluorine Radioisotopes; D019275:Radiopharmaceuticals; D012969:Sodium Fluoride; D013669:Technetium Tc 99m Medronate